期刊文献+

人胃癌SGC7901/VCR裸鼠移植瘤模型的建立及耐药性检测 被引量:7

Establishment of Xenograft Model in Nude Mice with Human Gastric Cancer SGC7901/VCR and Drug Resistance Detection
下载PDF
导出
摘要 目的建立人胃癌SGC7901/VCR裸鼠移植瘤模型,并检测其多药耐药性,为进行肿瘤多药耐药逆转剂的筛选和体内实验研究奠定基础。方法采用皮下接种法建立裸鼠移植瘤模型;观察裸鼠生长状况;移植瘤生长情况;进行瘤重及瘤体积比较;移植瘤P-gp耐药蛋白表达;原代培养细胞,检测移植瘤模型多药耐药性。结果人胃癌SGC7901/VCR裸鼠移植瘤组织病理学检查为低分化腺癌,移植瘤组织原代细胞培养后,P-gp表达强阳性+++,具有多药耐药性,模型建立成功。结论成功建立了人胃癌SGC7901/VCR裸鼠多药耐药移植瘤模型,为胃癌耐药研究提供了较理想的动物模型。 Objective To establish xenograft model in nude mice with human gastric cancer SGC7901/VCR and detect muhidmg resistance so as to lay the foundation for the screening of muhidrug re- sistance reversal agents of tumors and in vivo experimental study. Methods The subcutaneous vaccination was used to establish xenograft model in nude mice. The growth condition of nude mice and xenograft was ob- served. The tumor weight and volume were compared. The expression of P - gp drug - resistant protein of xen- ograft was observed. The cells were cultivated primarily. The multidrug resistance was detected in xenograft model. Results The xenograft model in nude mice with human gastric cancer SGC7901/VCR discovered low - differentiated adenocarcinoma in histopathology. After the culture of primary cells in xenograft tissue, P - gp expression indicated strong positive( +++ ), presenting muhidrug resistance and success of model estab- lishment. Conclusion The multidrug resistance xenograft model is established successfully by using human gastric cancer SGC7901/VCR in nude mice. It provides the quite satisfactory animal model for the drug re- sistance studv of zastric cancer.
机构地区 山西省中医院
出处 《世界中西医结合杂志》 2013年第4期358-360,共3页 World Journal of Integrated Traditional and Western Medicine
关键词 胃癌 SGC7901 VCR细胞 多药耐药 裸鼠移植瘤模型 Gastric Cancer SGC7901/VCR Cell Muhidrug Resistance Xenograft Model inNude Mice
  • 相关文献

参考文献8

二级参考文献26

  • 1郑玉玲.常用抗肿瘤手册[M].北京:中国医药科技出版社,1994.340.
  • 2Lenoardo E, Valente G, Cappia S, et al. Immunohistoehemical eval-uation of P-glycoprotein in human malignancies by monoclonal anti- body MC57[J]. Int J Cancer,1994, 57(6): 841-846.
  • 3Juliano RL, Ling V. A surface glycoprotein modulating drug permea- bility in Chinese hamster ovary cell mutants [J]. Biochim Biophys Acta,1976,455(I) :152-162.
  • 4Gollesman MM, Pastan 1. Biochemistry of multidrug resistance media- ted by the muhidrug transporter[J]. Annu Rev Biochem, 1993, 62: 385-427.
  • 5Labialle S, Gayet L, Marthinet E,et al. Transcriptional regulators of the human multidrug resistance 1 gene: recent views [J]. Biochem Pharmacol, 2002,64 ( 5-6 ) : 943-948.
  • 6Kao CH, Tsai SC, Liu TJ, et al. P-Glyeoprotein and muhidrug resist-ance-related protein expressions in relation to technetium-99m methox- yisobutylisonitrile seintimammography findings [J]. Cancer Res, 2001,61 (4) :1412-1414.
  • 7Ruiz G6mez M J, Souviron Rodriguez A, Martinez Morillo M. P-glyco- protein, a membrane pump that represents a barrier to chemotherapy in cancer patients [J]. An Med Interna, 2002, 19 (9) :477-485.
  • 8Loo TW, Clarke DM. Recent progress in understanding the mecha- nism of P-glycoprotein-mediated drug efflux [J]. J Membr Biol, 2005, 206(3) :173-185.
  • 9Sisodiya SM, Martinian L, Scheffer GL, et al. Vascular colocalization of P-glycoprotein, muhidrug-rcsistance associated protein 1, breast cancer resistance protein and major vault protein in human epilepto- genic pathologies [J]. N europathol Appl Neurobiol, 2006,32 (1) : 51-63.
  • 10郑玉玲,常用抗肿瘤手册,1994年,340页

共引文献33

同被引文献84

引证文献7

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部